ArticlePloS one2014
Comparing cutaneous research funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases with 2010 Global Burden of Disease results.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Interventions for the prevention of recurrent erysipelas and cellulitis.The Cochrane database of systematic reviews · 2017Pooled it
- Use of Clinical Public Databases in Hidradenitis Suppurativa Research.Interactive journal of medical research · 2025Article
- Global burden of bacterial skin diseases from 1990 to 2045: an analysis based on global burden disease data.Archives of dermatological research · 2025Article
- Impact of 970 nm photobiomodulation therapy on wound healing in cellular models of hidradenitis suppurativa.Lasers in medical science · 2021Article
- Fatal New-Onset Congestive Heart Failure Related to Adalimumab Use in a Patient with Relapsing Hidradenitis Suppurativa: A Case Report.The American journal of case reports · 2021Article
- The Burden of Skin and Subcutaneous Diseases in the United States From 1990 to 2017.JAMA dermatology · 2020Article
- A Call to Accelerate Hidradenitis Suppurativa Research and Improve Care-Moving Beyond Burden.JAMA dermatology · 2019Article
- Association of ERAP1 gene polymorphisms with the susceptibility to psoriasis vulgaris: A case-control study.Medicine · 2018Observational
- Global Burden of Skin Disease: Inequities and Innovations.Current dermatology reports · 2017Article
- Cumulative Life Course Impairment of Alopecia Areata.International journal of trichologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 12 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceDisease burden data helps guide research prioritization.
objectiveTo determine the extent to which grants issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) reflect disease burden, measured by disability-adjusted life years (DALYs) from Global Burden of Disease (GBD) 2010 project.
designTwo investigators independently assessed 15 skin conditions studied by GBD 2010 in the NIAMS database for grants issued in 2013. The 15 skin diseases were matched to their respective DALYs from GBD 2010.
settingThe United States NIAMS database and GBD 2010 skin condition disability data. MAIN OUTCOME(S) AND MEASURE(S): Relationship of NIAMS grant database topic funding with percent total GBD 2010 DALY and DALY rank for 15 skin conditions.
resultsDuring fiscal year 2013, 1,443 NIAMS grants were issued at a total value of $424 million. Of these grants, 17.7% covered skin topics. Of the total skin disease funding, 82% (91 grants) were categorized as "general cutaneous research." Psoriasis, leprosy, and "other skin and subcutaneous diseases" (ie; immunobullous disorders, vitiligo, and hidradenitis suppurativa) were over-represented when funding was compared with disability. Conversely, cellulitis, decubitus ulcer, urticaria, acne vulgaris, viral skin diseases, fungal skin diseases, scabies, and melanoma were under-represented. Conditions for which disability and funding appeared well-matched were dermatitis, squamous and basal cell carcinoma, pruritus, bacterial skin diseases, and alopecia areata. CONCLUSIONS AND RELEVANCE: Degree of representation in NIAMS is partly correlated with DALY metrics. Grant funding was well-matched with disability metrics for five of the 15 studied skin diseases, while two skin diseases were over-represented and seven were under-represented. Global burden estimates provide increasingly transparent and important information for investigating and prioritizing national research funding allocations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.